Two eyes with NIU-PS were diagnosed with glaucoma post-FA treatment: one eye was already diagnosed with papillitis and being steroid-responsive to pre-FA treatment; the other eye of a BCR-ABL-positive patient developed secondary glaucoma and was treated with PreserFlo®MicroShunt (Santen Pharmaceutical Co. Ltd., Osaka, Japan) 12 months post-FA implantation. Here, ABL1 is linked to optic papillitis.